Q1 EPS Estimate for Eton Pharmaceuticals Lifted by Analyst

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) – Equities research analysts at B. Riley lifted their Q1 2025 earnings estimates for Eton Pharmaceuticals in a research note issued on Sunday, April 27th. B. Riley analyst M. El-Saadi now expects that the company will earn $0.13 per share for the quarter, up from their previous estimate of $0.06. B. Riley currently has a “Buy” rating and a $24.00 price target on the stock. The consensus estimate for Eton Pharmaceuticals’ current full-year earnings is ($0.14) per share. B. Riley also issued estimates for Eton Pharmaceuticals’ Q2 2025 earnings at $0.06 EPS, Q3 2025 earnings at $0.11 EPS, FY2025 earnings at $0.64 EPS, FY2026 earnings at $1.48 EPS, FY2027 earnings at $1.86 EPS, FY2028 earnings at $2.23 EPS and FY2029 earnings at $2.46 EPS.

Eton Pharmaceuticals (NASDAQ:ETON) last posted its quarterly earnings data on Tuesday, March 18th. The company reported ($0.02) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.02). The business had revenue of $11.65 million for the quarter, compared to analysts’ expectations of $10.53 million. Eton Pharmaceuticals had a negative return on equity of 36.29% and a negative net margin of 15.81%.

Several other equities research analysts have also recently issued reports on the stock. HC Wainwright reissued a “buy” rating and issued a $33.00 target price on shares of Eton Pharmaceuticals in a research report on Wednesday, March 19th. Craig Hallum increased their price target on shares of Eton Pharmaceuticals from $23.00 to $26.00 and gave the stock a “buy” rating in a research note on Wednesday, March 19th.

Eton Pharmaceuticals Trading Up 3.2 %

Shares of NASDAQ:ETON opened at $16.49 on Wednesday. The firm has a market cap of $442.23 million, a price-to-earnings ratio of -74.95 and a beta of 1.34. The stock’s 50-day moving average price is $14.11 and its two-hundred day moving average price is $13.11. Eton Pharmaceuticals has a 12-month low of $3.18 and a 12-month high of $18.41.

Institutional Trading of Eton Pharmaceuticals

Institutional investors have recently modified their holdings of the company. Tower Research Capital LLC TRC acquired a new position in Eton Pharmaceuticals during the fourth quarter valued at approximately $86,000. Jefferies Financial Group Inc. purchased a new position in shares of Eton Pharmaceuticals in the 4th quarter valued at $133,000. Point72 Asia Singapore Pte. Ltd. lifted its holdings in shares of Eton Pharmaceuticals by 18.3% during the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 10,561 shares of the company’s stock valued at $141,000 after acquiring an additional 1,634 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in Eton Pharmaceuticals during the 4th quarter worth $147,000. Finally, Bank of America Corp DE increased its holdings in Eton Pharmaceuticals by 5,422.4% in the 4th quarter. Bank of America Corp DE now owns 11,100 shares of the company’s stock valued at $148,000 after purchasing an additional 10,899 shares in the last quarter. Hedge funds and other institutional investors own 27.86% of the company’s stock.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.